Clinical Trials

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03258567 2026-05-22

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

40 enrolled

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Hodgkin Disease

NCT07013565 2026-05-20

ACCELERATE

20 enrolled

Phase 2 Not yet recruiting

Lymphoma, Large-Cell, Anaplastic

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

15 enrolled

Hodgkin Disease

NCT02693535 2026-05-15

TAPUR

4,200 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

68 enrolled

DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

64 enrolled

Lymphoma, Neoplasm Metastasis

NCT04652960 2026-05-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

38 enrolled

Mycosis Fungoides, Sezary Syndrome

NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Phase 1 Recruiting

32 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01703949 2026-05-12

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

28 enrolled 11 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

54 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04205409 2026-05-12

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2 Completed

20 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05723055 2026-05-08

NAHL

9 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

50 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT03927105 2026-05-07

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Completed

4 enrolled 15 charts

Phase 3 Active not recruiting

Lymphoma, T-Cell, Peripheral

NCT03907488 2026-05-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 1 FDA

Hodgkin Disease

NCT03057795 2026-05-01

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

62 enrolled 8 charts

Hodgkin Disease

NCT02879695 2026-04-29

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

28 enrolled 16 charts

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04134325 2026-04-17

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Phase EARLY_PHASE1 Active not recruiting

10 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06767956 2026-04-13

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Withdrawn

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02681302 2026-04-03

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

Lymphoma, Multiple Myeloma

NCT03297606 2026-03-27

CAPTUR

720 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Recruiting

54 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease

NCT05255601 2026-02-25

RELATIVITY-069

Phase 1/2 Completed

5 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Phase 1/2 Active not recruiting

82 enrolled

Hodgkin Disease

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04938232 2026-02-05

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

13 enrolled 19 charts

Hodgkin Disease

NCT04401774 2026-01-27

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Phase 2 Completed

14 enrolled

CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04022980 2025-12-30

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

Phase 1 Completed

14 enrolled

Lymphoma, Neurologic Manifestations

NCT06984146 2025-11-26

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

54 enrolled

Hodgkin Disease

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03016871 2025-10-20

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

78 enrolled 15 charts

Hodgkin Disease

NCT07209059 2025-10-06

FINISH-HL

30 enrolled

Phase 1/2 Active not recruiting

Hodgkin Disease

NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

36 enrolled